维普中文期刊产品整合服务
256篇 您的检索式:作者名="Marwaha"
    题名 作者 年代 出处 被引量
1Current testing strategies for hepatitis C virus infection in blood donors and the way forward显示文摘Screening tests for blood donations are based upon sensitivity,cost-effectiveness and their suitability for high-throughput testing.Enzyme immunoassay(EIAs)for hepatitis C virus(HCV)antibodies were the initial screening tests introduced.The'first generation'antibody EIAs detected seroconversion after unduly long infectious window period.Improved HCV antibody assays still had an infectious window period around 66 d.HCV core antigen EIAs shortened the window period considerably,but high costs did not lead to widespread acceptance.A fourth-generation HCV antigen and antibody assay(combination EIA)is more convenient as two infectious markers of HCV are detected in the same assay.Molecular testing for HCV-RNA utilizing nucleic acid amplification technology(NAT)is the most sensitive assay and shortens the window period to only4 d.Implementation of NAT in many developed countries around the world has resulted in dramatic reductions in transfusion transmissible HCV and relative risk is now<1 per million donations.However,HCV serology still continues to be retained as some donations are serology positive but NAT negative.In resource constrained countries HCV screening is highly variable,depending upon infrastructure,trained manpower and financial resource.Rapid tests which do not require instrumentation and are simple to perform are used in many small and remotely located blood centres.The sensitivity as compared to EIAs is less and wherever feasible HCV antibody EIAs are most frequently used screening assays.Efforts have been made to implement combined antigen-antibody assays and even NAT in some of these countries.Neelam Marwaha Suchet Sachdev 2014World Journal of Gastroenterology2014,20,11:9
2Anti-HBc screening in Indian blood donors:Still an unresolved issue显示文摘AIM:To study the seroprevalence of antibody to hepatitis B core antigen (anti-HBc) in healthy blood donors negative for HBsAg and to evaluate whether anti-HBc detection could be adopted in India as a screening assay for HBV in addition to HBsAg. METHODS: A total of 1700 serum samples collected from HBsAg-negative healthy blood donors were tested for the presence of anti-HBc antibody (IgM + IgG). All samples reactive for anti-HBc antibody were then investigated for presence of anti-HBs and for liver function tests (LFTs). One hundred serum samples reactive for anti-HBc were tested for HBV DNA by PCR method. RESULTS: Out of 1700 samples tested, 142 (8.4%) blood samples were found to be reactive for anti-HBc. It was signif icantly lower in voluntary (6.9%) as compared to replacement donors (10.4%, P = 0.011). Seventy- two (50.7%) anti-HBc reactive samples were also reactive for anti-HBs with levels > 10 mIU/mL and 70 (49.3%) samples were non-reactive for anti-HBs, these units were labeled as anti-HBc-only. These 142 anti-HBc reactive units were also tested for liver function test. HBV DNA was detected in only 1 of 100 samples tested. CONCLUSION: Keeping in view that 8%-18% of donor population in India is anti-HBc reactive, inclusion of anti- HBc testing will lead to high discard rate. Anti-HBs as proposed previously does not seem to predict clearance of the virus. Cost effectiveness of introducing universalanti-HBc screening and discarding large number of blood units versus considering ID NAT (Individual donor nuclic acid testing) needs to be assessed.Hari Krishan Dhawan Neelam Marwaha Ratti Ram Sharma Yogesh Chawla Beenu Thakral Karan Saluja Sanjeev Kumar Sharma Manish K Thakur Ashish Jain 2008World Journal of Gastroenterology2008,14,34:8
3Autologous bone marrow derived stem cell therapy in patients with type 2 diabetes mellitus-defining adequate administration methods显示文摘AIM To carry out randomized trial for evaluating effects of autologous bone marrow derived stem cell therapy(ABMSCT) through different routes.METHODS Bone marrow aspirate was taken from the iliac crest of patients. Bone marrow mononuclear cells were separatedand purified using centrifugation. These cells were then infused in a total of 21 patients comprising three groups of 7 patients each. Cells were infused into the superior pancreaticoduodenal artery(Group Ⅰ), splenic artery(Group Ⅱ) and through the peripheral intravenous route(Group Ⅲ). Another group of 7 patients acted as controls and a sham procedure was carried out on them(Group Ⅳ). The cells were labelled with the PET tracer F18-FDG to see their homing and in vivo distribution. Data for clinical outcome was expressed as mean ± SE. All other data was expressed as mean ± SD. Baseline and post treatment data was compared at the end of six months, using paired t-test. Cases and controls data were analyzed using independent t-test. A probability(P) value of < 0.05 was regarded as statistically significant. Measures of clinical outcome were taken as the change or improvement in the following parameters:(1) C-peptide assay;(2) HOMA-IR and HOMA-B;(3) reduction in Insulin dose; subjects who showed reduction of insulin requirement of more than 50% from baseline requirement were regarded as responders; and(4) reduction in HbA 1c. RESULTS All the patients, after being advised for healthy lifestyle changes, were evaluated at periodical intervals and at the end of 6 mo. The changes in body weight, body mass index, waist circumference and percentage of body fat in all groups were not significantly different at the end of this period. The results of intra-group comparison before and after ABMSCT at the end of six months duration was as follows:(1) the area under C-peptide response curve was increased at the end of 6 mo however the difference remained statistically non-significant(P values for fasting C-peptide were 0.973, 0.103, 0.263 and 0.287 respectively and the P values for stimulated C-peptide were 0.989, 0.395, 0.325 and 0.408 respectively for groups Ⅰ?to Ⅳ);(2) the Insulin sensitivity indices of HOMA IR and HOMA B also did not show any significant differences(P values for HOMA IR were 0.368, 0.223, 0.918 and 0.895 respectively and P values for HOMA B were 0.183, 0.664, 0.206 and 0.618 respectively for groups Ⅰto Ⅳ);(3) Group Ⅰshowed a significant reduction in Insulin dose requirement(P < 0.01). Group Ⅱ patients also achieved a significant reduction in Insulin dosages(P = 0.01). The Group Ⅰand Group Ⅱ patients together constituted the targeted group wherein the feeding arteries to pancreas were used for infusing stem cells. Group Ⅲ, which was the intravenous group, showed a non-significant reduction in Insulin dose requirement(P = 0.137). Group Ⅳ patients which comprised the control arm also showed a significant reduction in Insulin dosages at the end of six months(P < 0.05); and(4) there was a non-significant change in the Hb A1 c levels at the end of 6 mo across all groups(P = 0.355, P = 0.351, P = 0.999 and P = 0.408 respectively for groups Ⅰto Ⅳ). CONCLUSION Targeted route showed a significant reduction in Insulin requirement at the end of six months of study period whereas the intravenous group failed to show reduction.Vikas Sood Anil Bhansali Bhagwant Rai Mittal Baljinder Singh Neelam Marwaha Ashish Jain Niranjan Khandelwal 2017World Journal of Diabetes2017,8,7:6
4Clinical significance of epicardial fat measured using cardiac muhislice comput- ed tomography显示文摘Sarin S Wenger C Marwaha A 2008Am J Cardiol2008,102,6:1
5Management of nutritional rickets in Indian children: a randomized controlled trial 显示文摘Aggarwal V Seth A Marwaha RK 2013J Trop Pediatr2013,59,2:1
6Prevalence of thy-roid au2 to immunity in sporadic idiopathic hypoparathyroidism in comparison to type 1 diabetes and premature ovarian failure显示文摘Goswami R Marwaha RK Goswami D 0,,11:1
7Studies on the applicability of alginate-entrapped naringinase for the debittering of kinnow juice 显示文摘Puri M Marwaha S S Kothari R M 1996Enzyme & Microbial Technology1996,18,4:1
8Prevalence of thyroid autoimmunity in sporadic idiopathic hypoparathyroid- ism in comparison to type 1 diabetes and prematuc ovarian failure显示文摘Goswami R Marwaha RK Goswami D 2006J Clin Endocrinol Metab2006,91,11:1
9Residual goitre in the postiodization phase: iodine estatus , thiocyanate exposure and autoimmunity显示文摘Marwaha RK Tandon N Gupta N 2003Chin Endocrinal Coxf )2003,59,67:1
10Formalizing BPEL-TC throughΠ-calculus显示文摘Marwaha P Banati H Bedi P 2013International Journal of Web&Semantic Technology2013,4,3:1
11Recent trends in Enzymatic Coversion of Ceohalosporin C to 7 Amino CepHalosporanic acid(7-ACA)显示文摘Parmar A Kurmar H Marwaha Setal 1998CritRev Biotechnol1998,18,1:1
12Comparative kinetic characterization of soluble and alginate entrapped naringinase显示文摘Puri M Marwaha S S Kothari R M 0,,:1
13Tempol reduces oxidative stress and restores renal dopamine D1-like receptor-G protein coupling and function in hyperglycemic rats显示文摘Marwaha A Lokhandwala MF 2006Am J Physiol Renal Physiol2006,291,:1
14Protein energy malnutrition and skeletal muscle wasting in childhood acute lymphoblastic leukemia 显示文摘Kumar R Marwaha RK Bhalla AK 2000Indian Pediatx2000,37,7:1
15The Effect of Foreign Capital and Imports on Economic Growth:Further Evidence from Four Asian Countries(1970-1998)显示文摘Kanta Marwaha Akbar Tavakoli 2004Journal of Asian Economics2004,,15:1
16An epidemic of encephalitis in Haryana :serologic evidence of Japanese encephalitis in a few patients显示文摘Prasad S R Kumar V Marwaha R K 1993Indian Pediat1993,30,7:1
17Severe ABO hemolytic disease of new born with a positive direct an tiglobulin tes 显示文摘Marwaha N Dhawan H Thakral B 2009t Indian J Patho-1 Microbiol2009,52,2:1
18Consensus and controversies in platelet transfusion 显示文摘Marwaha N Sharma RR 2009Transfus Apher Sci2009,41,2:1
19Consensus and controversies in platelet transfusion显示文摘Neelam Marwaha R.R. Sharma 2009Transfusion and Apheresis Science2009,,2:1
20Correlation between bone mineral density measured by peripheral and central dual energy X-ray absorptiometry in healthy Indian children and adolescents aged 10-18 years显示文摘Channabasappa S Marwaha R K Tandon N 2013Journal of pediatric endocrinology&metabolism2013,26,78:1
返回顶部 每页显示:
共13页 首页 上一页 第1页 下一页 末页 /13 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费